Navigation Links
JAG Media Holdings, Inc. Announces Update of the Status of its Proposed Acquisition of CardioGenics Inc.
Date:4/30/2009

BOCA RATON, Fla., April 30 /PRNewswire-FirstCall/ -- JAG Media Holdings, Inc. (OTC Bulletin Board: JAGH) announced today an update of the status of its proposed acquisition of CardioGenics Inc. by a to-be-created Canadian subsidiary of JAG Media, for which the parties entered into a Letter of Intent on March 12, 2009. Currently, the parties are attending to various closing matters such as the preparation and negotiation of the required documents in connection with the acquisition, preparation of the required audited financial statements for CardioGenics and establishment of the two Canadian subsidiaries of JAG Media required in connection with the transaction. Both parties are dedicating their full resources to execute all the matters in preparation for closing. Based upon the current status of the various closing matters being attended to by the parties, the parties now project a closing date of May 29, 2009.

Notwithstanding the Letter of Intent, there is no assurance that the definitive documentation called for in the Letter of Intent will ever be executed, or if executed, that the proposed transaction between JAG Media and CardioGenics will be consummated. Further, to the extent that definitive agreements are reached, no assurances can be given that any such agreements will be entered into consistent with the current expectations of JAG Media and CardioGenics, as contemplated by the terms of the Letter of Intent.

About JAG Media Holdings, Inc.

JAG Media Holdings, Inc. is a provider of Internet-based equities research and financial information that offers its subscribers a variety of stock market research, news and analysis, including "JAG Notes", the Company's flagship early morning consolidated research product.

About CardioGenics Inc.

CardioGenics develops technology and products targeting the immunoassay segment of the In-Vitro Diagnostic testing market. CardioGenics has developed the QL Care Analyzer, a proprietary Point Of Care immuno-analyzer, which will run a number of diagnostic tests under development by CardioGenics, the first of which will be a series of cardiovascular diagnostic tests. As part of its core proprietary technology, CardioGenics has also developed a proprietary method for silver coating paramagnetic microspheres (a fundamental platform component of immunoassay equipment), which improve instrument sensitivity to light. CardioGenics' principal offices are located in Mississauga, Ontario, Canada.


'/>"/>
SOURCE JAG Media Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Center to Expose and Close Animal Factories to Hold Media Teleconference Tomorrow to Discuss Smithfield Operations, Connection to Swine Flu, Health and Enviro Impacts
2. AUDIO from Medialink and the McKesson Settlement Administrator: McKesson Settlement
3. BioTech Medical Well-Positioned to Immediately Respond to Swine Flu Emergency with SDC-Based SpectraSan 24 Disinfectant
4. Locum Leaders Links Physicians to New Jobs and Clinical Education Through Social Media
5. Media Urged to Correct Inaccurate References to Swine Flu
6. Media registration now open for TCT 2009
7. Dr. David Williams Scoops National Media on PSA Effectiveness -- by 17 Years
8. AUDIO from Medialink and Prescription Solutions: Prescription Solutions - A Drug Interaction Alert
9. GlobalMedia Launches Telemedicine Product for Ambulatory and Emergency Care
10. AdEx Media Introduces RezActiv(TM)
11. Media Statement on Lechuza Polo Team Incident
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... a new partnership with the Rhode Island Consortium for Autism Research and Treatment ... opportunity for children with autism spectrum disorder (ASD) to see films in an ...
(Date:2/23/2017)... ... 2017 , ... Curemark, LLC announced today that the Blüm Study, a Phase ... 3-8 with Autism, is now enrolling at three new sites. These new sites are ... , “There are currently no approved drugs that address the core symptoms of ...
(Date:2/22/2017)... ... February 22, 2017 , ... When ... new healthcare contact center in Georgia, PENETRON Specialty Products (PSP) provided the solution. ... healthcare systems recently invested $51 million to purchase and renovate the 185,000 square-foot ...
(Date:2/22/2017)... Angeles, CA (PRWEB) , ... February 22, 2017 , ... ... detox treatment to the thousands of individuals who have recently fallen victim to America’s ... hospital in Orange County, California, where they are free from the shame, stigma, ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... leads to fewer trips the emergency room, fewer hospital admissions, and better blood ... of Managed Care® (AJMC®) finds. The study can be found here . ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , Feb. 23, 2017   SeraCare Life ... global in vitro diagnostics manufacturers and clinical laboratories, ... "Catalyzing Implementation of NGS-Based Tests" to be hosted ... 2017 at 11am Eastern Standard Time (US). ... highlight the need for improved performance and global ...
(Date:2/23/2017)... -- ML Capital Group, Inc. (USOTC: MLCG) today announced ... , a Colorado -based cannabis tourism company. ... (USOTC: PURA) to enter Colorado,s $19 billion ... Tours acquisition announced today is intended to accelerate MLCG,s ... ...
(Date:2/23/2017)... DIEGO , Feb. 23, 2017 ... a clinical-stage oncology drug development company, announces that ... and Drug Administration (FDA) authorizing the initiation a ... therapeutic treatment for pancreatic cancer. MVT-1075 ( 177 ... radioimmunotherapy (RIT). MabVax plans to initiate the phase ...
Breaking Medicine Technology: